Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Abigail M. Johnston, JD
Advertisement
Articles by Abigail M. Johnston, JD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
3
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
4
Region-Based Genetic Disorders Affect Cancer Treatment Decisions
5
